Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PALO ALTO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat...
-
PALO ALTO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat...
-
PALO ALTO, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies that...
-
Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer
PALO ALTO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies...
-
-- Orphan Drug Designation and Breakthrough Therapy Designation Previously Granted by U.S. Food and Drug Administration -- -- Company Plans to Initiate a Phase 3 Clinical Trial of Eflornithine...
-
PALO ALTO, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies that...